Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
NCT04688736

Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-08-05

6642

Participants Needed

4

Research Sites

338 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, randomized, double-blind controlled trial to evaluate the efficacy of placebo versus chlorpheniramine for the prevention of allergic transfusion reactions.

CONDITIONS

Official Title

Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 to 65 years old
  • Diagnosed with a hematological disorder requiring blood product transfusions (such as suspended red blood cells, apheresis platelets, or fresh frozen plasma)
  • Able to fully understand and voluntarily sign informed consent forms
Not Eligible

You will not qualify if you...

  • History of allergic diseases
  • Experienced at least 1 moderate/severe or 2 mild allergic reactions previously
  • Received glucocorticoid or allergy drugs within 24 hours before blood transfusion
  • Transfused with washed red blood cells
  • Received allo-hematopoietic stem cell transplantation before
  • Have heart failure
  • Suffer from lasting cardiovascular or cerebrovascular disease effects
  • Pregnant or nursing women
  • Unable to understand or follow study procedures

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Anhui Provincial Hospital

Hefei, Anhui, China

Not Yet Recruiting

2

Zhoukou Central Hospital

Zhoukou, Henan, China

Actively Recruiting

3

The Second Affilated Hospital of Shandong First Medical University

Tai’an, Shandong, China

Actively Recruiting

4

Regenerative Medicine Center

Tianjin, Tianjin Municipality, China

Actively Recruiting

Loading map...

Research Team

J

Jun Shi, PhD

CONTACT

J

Jingyu Zhao, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here